STAT1 expression is known to be higher in the luminal (ER-positive) molecular subtype of breast cancer relative to HER2-positive or triple-negative breast disease [20], but we are not aware of any reports of its role in endocrine-resistant breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.